



**International
Product Portfolio
2024-2025**

AVAILABLE

PRODUCT	PHARMACEUTICAL FORM	STRENGTH	THERAPEUTIC AREA
Apixaban	<i>F.c. tablets</i>	2.5mg, 5mg	Oral Anticoagulant
Calcium Folate injectable	<i>Solution for injection</i>	200 mg /20 ml	Detoxifyingagents for antineoplastic treatment
Linagliptin	<i>F.c. tablets</i>	5mg	Oral Antidiabetic
Micafungin	<i>Powder for solution for infusion</i>	50mg/10ml 100mg/10ml	Antifungal
Rivaroxaban	<i>F.c. tablets</i>	2.5mg, 10mg 15mg, 20mg	Oral Anticoagulant
Sitagliptin Hydrochloride + Metformin	<i>F.c. tablets</i>	50mg +850mg 50mg+1000mg	Oral Antidiabetic
Sitagliptin Hydrochloride	<i>F.c. tablets</i>	25mg, 50mg 100mg	Oral Antidiabetic
Sugammadex	<i>Solution for injection</i>	100mg/ml	Reversion of the effect of the muscle relaxants rocuronium and vecuronium.
Ticagrelor	<i>F.c. tablets</i>	60mg, 90mg	Platelet aggregation inhibitor

UNDER DEVELOPMENT

PRODUCT	PHARMACEUTICAL FORM	STRENGTH	THERAPEUTIC AREA
Avatrombopag	<i>F.c tablets</i>	20mg	Thrombocytopenia
Bempedoic acid	<i>F.c tablets</i>	180mg	LDL Cholesterol

UNDER DEVELOPMENT

PRODUCT	PHARMACEUTICAL FORM	STRENGTH	THERAPEUTIC AREA
Bempedoic acid + Ezetimibe	<i>F.c. tablets</i>	180mg+10mg	LDL Cholesterol
Dapagliflozin	<i>F.c. tablets</i>	5mg, 10mg	Oral Antidiabetic
Dapagliflozin + Metformin	<i>F.c. tablets</i>	5mg+850mg, 5mg+1000mg	Oral Antidiabetic
Empagliflozin +Linagliptin	<i>F.c. tablets</i>	10mg+5mg, 25mg+5mg	Anti-diabetic/ Hypoglycemia/ Sugar Levels
Linagliptin + Metformin	<i>F.c. tablets</i>	2.5/850mg, 2.5/1000mg	Oral Antidiabetic
Lisdexamfet-amine Dimesylate	<i>Capsules</i>	10mg, 20mg 30mg, 40mg 50mg, 60mg	CNS/Neurological
Mirabegron/ Solifenacin	<i>F.c. tablets</i>	TBC	Urology
Riociguat	<i>F.c. tablets</i>	0.5mg, 1mg 1.5mg, 2mg, 2.5mg	Cardiovascular/Blood Pressure/Heart Disease
Safinamide Mesylate	<i>F.c. tablets</i>	50mg, 100mg	CNS/ Parkinson

CONTACT

Athens

Business Development & Licensing
Naousis 31 Athens, 10447, Greece
Tel.: +30 210 341 8889
Fax.: + 30 210 866 1262
E-mail.: bd@pharmazac.com